After attending this activity, participants will be able to:
• Evaluate new efficacy and safety data of frontline treatments for patients with advanced classical Hodgkin lymphoma (cHL)
• Discuss and interpret trial results in order to better select treatment regimens for advanced cHL in the frontline setting
• Apply new evidence to the clinical management of patients with stage IV cHL through discussion of case scenarios